Lunai Bioworks Inc
renovarobio.comWhat Do They Do?
Develops AI-based biomedical research tools and experimental programs for pharmaceutical companies, healthcare providers and academic institutions, alongside cell and gene therapies and drug-delivery technology.
10-K for FY2026, filed Oct 13, 2026Lunai Bioworks Inc. is an AI-driven biotechnology company focused on precision medicine, biomarker discovery, and therapeutic development…View ↗
Renovaro Biosciences is a biotechnology company intending, if the necessary funding is obtained, to develop advanced allogeneic cell and…View ↗
BioSymetrics is a biomedical artificial intelligence company focused on integrating multimodal data sources, including genomics, imaging…View ↗
BioSymetrics collaborates with pharmaceutical companies, healthcare providers, and academic institutions to co-develop analytical tools and…View ↗
On May 1, 2026, Lunai Bioworks, through its wholly owned subsidiary Lunai Bioworks IP, Inc., acquired Neurobridge IP Holdings Incorporated…View ↗
How Do They Make Money?
A research customer pays a fixed fee for services over an 18-month agreement; the company bills amounts in advance before providing those services.
10-K for FY2026, filed Oct 13, 2026Revenue Recognition – The Company recognizes revenue in accordance with ASC 606 when control of promised services is transferred to the…View ↗
$52K
-
10-K for FY2026, filed Oct 13, 2026
$52K ↗
Who Are Their Customers?
BioSymetrics collaborates with pharmaceutical companies, healthcare providers and academic institutions to develop analytical tools and research programs.
10-K for FY2026, filed Oct 13, 2026BioSymetrics collaborates with pharmaceutical companies, healthcare providers, and academic institutions to co-develop analytical tools and…View ↗
Do Revenues Turn Into Profits?
No. It lost $3.6M in FY2026.
Who Do They Compete With?
Competes with Recursion Pharma and insitro
10-K for FY2026, filed Oct 13, 2026BioSymetrics similarly operates in a highly competitive market with companies including Recursion Pharma and insitro also focused on…View ↗
Loading...
